The Emerging Benefits of Immunotherapy and Targeted Therapy

There have been many advances in the systemic therapy for lung cancer. Novel agents carry with them unique toxicities and considerations for multidisciplinary cancer care. The understanding of unique toxicities with combination therapy (IO and RT) and novel agents (targeted therapies, ADCs, bispecific antibodites) is essential for optimal patient care.

It is essential for multidisciplinary lung cancer providers to have an understanding of combination therapy studies with IO and RT. It is also important to recognize the unique spectrum of activity and toxicity for newly approved agents and drugs in development, notably pneumonitis and dermtologic toxicities.

The session on the emerging benefits of targeted therapy and immunotherapy is intended to bridge the disciplines by providing data and research landscape updates on the combinations of immunotherapy and SBRT for early-stage lung cancer. Futhermore, the non-classical targeted therapies and their unique spectrum of efficacy and toxicity will be reviewed. These therapies have toxicities and considerations of importance for the multidisciplinary team. This overview will familiarize members of the multidisciplinary team on these recent therapy updates.

Target Audience

This meeting is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists and pulmonologists.

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Understand the landscape of investigation for stage I NSCLC combining IO and RT.
  • Become familiar with the non-TKI targeted therapies, their application, estimate efficacy, and toxicities;
  • Understand the ADCs and Bispecific antibodies being used to treat NSCC, which populations, and their toxicities.
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.
Course opens: 
12/03/2023
Course expires: 
12/02/2025
Cost:
$0.00
Part of: 
2023 Multidisciplinary Thoracic Cancers Symposium onDemand
Rating: 
0

Moderator:

  • Jamie Craft, MD

Speakers:

  • Narek Shaverdian, MD
  • Joe Chang, MD, PhD
  • Sally Lau, MD
  • Jia Lou, MD

Faculty:
A list of all meeting faculty and Individual presenter disclosures are linked to their names in the Schedule of Events.

Planning Committee:
A list of all meeting planning committee members and their individual disclosures can be found on the Planning Committee website page.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.